Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update

HDV infection frequently causes progression to cirrhosis and hepatocellular carcinoma (HCC). In summer 2020, the first potentially effective drug Bulevirtide (BLV) has been approved for the treatment of HDV by the EMA. BLV is a synthetic N-acylated pre-S1 lipopeptide that blocks the binding of HBsAg...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferenci, Peter, Reiberger, Thomas, Jachs, Mathias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688382/
https://www.ncbi.nlm.nih.gov/pubmed/36428959
http://dx.doi.org/10.3390/cells11223531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688382/
https://www.ncbi.nlm.nih.gov/pubmed/36428959
http://dx.doi.org/10.3390/cells11223531

Ejemplares similares